Characterizing How Sponsor Companies are Operationalizing the Transition from Traditional to Risk-Based and Centralized Monitoring in Clinical Trials
Therapeutic Innovation & Regulatory Science · 19.11.2026
DOI: 10.1007/s43441-026-01072-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 19.11.2026. Verfasst von Hana Do und 6 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Do, H., Harper, B., Appel, J. S., Kinasiewicz, A., Valenzuela, M., Benedict, J., & Getz, K. (2026). Characterizing How Sponsor Companies are Operationalizing the Transition from Traditional to Risk-Based and Centralized Monitoring in Clinical Trials. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-026-01072-1
Vancouver
Do H, Harper B, Appel JS, Kinasiewicz A, Valenzuela M, Benedict J, et al. Characterizing How Sponsor Companies are Operationalizing the Transition from Traditional to Risk-Based and Centralized Monitoring in Clinical Trials. Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-026-01072-1
BibTeX
@article{Do2026,
author = {Do, Hana and Harper, Beth and Appel, Julie S. and Kinasiewicz, Andrzej and Valenzuela, Miguel and Benedict, Joanne and Getz, Kenneth},
title = {Characterizing How Sponsor Companies are Operationalizing the Transition from Traditional to Risk-Based and Centralized Monitoring in Clinical Trials},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2026},
doi = {10.1007/s43441-026-01072-1}
}
EUVIMED